Expert Interview
A Third Look: Discussing Current Treatments for Eosinophilic Esophagitis (EoE) and the Potential of EP-104GI from Eupraxia Pharmaceuticals
Ticker(s): EPRX, SNY, TAK, AZN, GSK, MRKInstitution: University of Colorado
- Associate Professor of Pediatrics at University of Colorado
- Manages over 1300 EoE patients in clinic and familiar with investigational therapies
- Research interests are in eosinophilic esophagitis and eosinophilic gastrointestinal diseases.
How many EoE patients do you manage?
Added By: wilson_adminHow are EoE patients currently being managed?
Added By: wilson_adminWhere would EP-104GI fit into your treatment algorithm?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
